Wall Street Expects Intellia Therapeutics Stock to Climb 107%. Is That Too Optimistic?
Sometimes even the professionals put the horse before the cart. For instance, Wall Street analysts are currently predicting that shares of the gene editing therapy biotech Intellia Therapeutics (NASDAQ: NTLA) will rise by 107% to reach a price of more than $87 within the next 12 months.
Is that estimate too sunny to be plausible, or are the company's shareholders in for a treat? As it turns out, the answer to both of those questions is probably yes. Here's why.
Analysts are almost certainly banking on the occurrence of several catalysts that will be necessary for Intellia to meet their price target by a year from now. All the potential catalysts pertain to milestones with a trio of its gene therapies in development.
Source Fool.com